170 related articles for article (PubMed ID: 28336299)
21. Effects of genetic polymorphisms on the OCT1 and OCT2-mediated uptake of ranitidine.
Meyer MJ; Seitz T; Brockmöller J; Tzvetkov MV
PLoS One; 2017; 12(12):e0189521. PubMed ID: 29236753
[TBL] [Abstract][Full Text] [Related]
22. Transport of asymmetric dimethylarginine (ADMA) by cationic amino acid transporter 2 (CAT2), organic cation transporter 2 (OCT2) and multidrug and toxin extrusion protein 1 (MATE1).
Strobel J; Müller F; Zolk O; Endreß B; König J; Fromm MF; Maas R
Amino Acids; 2013 Oct; 45(4):989-1002. PubMed ID: 23864433
[TBL] [Abstract][Full Text] [Related]
23. 3D-QSAR analysis of the interactions of flavonoids with human organic cation transporter 2.
Bi Y; Wang X; Li H; Tian Y; Han L; Gui C; Zhang Y
Toxicol Lett; 2022 Sep; 368():1-8. PubMed ID: 35901987
[TBL] [Abstract][Full Text] [Related]
24. Investigation of the role of organic cation transporter 2 (OCT2) in the renal transport of guanfacine, a selective α2A-adrenoreceptor agonist.
Li X; Sun X; Chen J; Lu Y; Zhang Y; Wang C; Li J; Zhang Q; Zhao D; Chen X
Xenobiotica; 2015 Jan; 45(1):88-94. PubMed ID: 25115365
[TBL] [Abstract][Full Text] [Related]
25. Substrate-dependent ligand inhibition of the human organic cation transporter OCT2.
Belzer M; Morales M; Jagadish B; Mash EA; Wright SH
J Pharmacol Exp Ther; 2013 Aug; 346(2):300-10. PubMed ID: 23709117
[TBL] [Abstract][Full Text] [Related]
26. Proximal tubular secretion of creatinine by organic cation transporter OCT2 in cancer patients.
Ciarimboli G; Lancaster CS; Schlatter E; Franke RM; Sprowl JA; Pavenstädt H; Massmann V; Guckel D; Mathijssen RH; Yang W; Pui CH; Relling MV; Herrmann E; Sparreboom A
Clin Cancer Res; 2012 Feb; 18(4):1101-8. PubMed ID: 22223530
[TBL] [Abstract][Full Text] [Related]
27. Involvement of Organic Cation Transporters in the Kinetics of Trimethylamine N-oxide.
Miyake T; Mizuno T; Mochizuki T; Kimura M; Matsuki S; Irie S; Ieiri I; Maeda K; Kusuhara H
J Pharm Sci; 2017 Sep; 106(9):2542-2550. PubMed ID: 28479364
[TBL] [Abstract][Full Text] [Related]
28. Incorporation of a Biguanide Scaffold Enhances Drug Uptake by Organic Cation Transporters 1 and 2.
Obianom ON; Coutinho AL; Yang W; Yang H; Xue F; Shu Y
Mol Pharm; 2017 Aug; 14(8):2726-2739. PubMed ID: 28699756
[TBL] [Abstract][Full Text] [Related]
29. Interactions of crizotinib and gefitinib with organic anion-transporting polypeptides (OATP)1B1, OATP1B3 and OATP2B1: gefitinib shows contradictory interaction with OATP1B3.
Sato T; Ito H; Hirata A; Abe T; Mano N; Yamaguchi H
Xenobiotica; 2018 Jan; 48(1):73-78. PubMed ID: 28005438
[TBL] [Abstract][Full Text] [Related]
30. Interaction of beta-blockers with the renal uptake transporter OCT2.
Bachmakov I; Glaeser H; Endress B; Mörl F; König J; Fromm MF
Diabetes Obes Metab; 2009 Nov; 11(11):1080-3. PubMed ID: 19740083
[TBL] [Abstract][Full Text] [Related]
31. Crizotinib effects on creatinine and non-creatinine-based measures of glomerular filtration rate.
Camidge DR; Brosnan EM; DeSilva C; Koo PJ; Chonchol M
J Thorac Oncol; 2014 Nov; 9(11):1634-7. PubMed ID: 25436798
[TBL] [Abstract][Full Text] [Related]
32. Effect of 7-ketocholesterol incorporation on substrate binding affinity and turnover rate of the organic cation transporter 2 (OCT2).
Xiu F; Console L; Indiveri C; Su S; Wang T; Visentin M
Biochem Pharmacol; 2024 Feb; 220():116017. PubMed ID: 38176620
[TBL] [Abstract][Full Text] [Related]
33. Enhanced and Persistent Inhibition of Organic Cation Transporter 1 Activity by Preincubation of Cyclosporine A.
Panfen E; Chen W; Zhang Y; Sinz M; Marathe P; Gan J; Shen H
Drug Metab Dispos; 2019 Nov; 47(11):1352-1360. PubMed ID: 31427432
[TBL] [Abstract][Full Text] [Related]
34. The conditional stimulation of rat organic cation transporter 2, but not its human ortholog, by mesoridazine: the possibility of the involvement of the high-affinity binding site of the transporter in the stimulation.
Hyung S; Pyeon W; Park JE; Song YK; Chung SJ
J Pharm Pharmacol; 2017 Nov; 69(11):1513-1523. PubMed ID: 28809437
[TBL] [Abstract][Full Text] [Related]
35. Inhibitory interaction of flavonoids with organic cation transporter 2 and their structure-activity relationships for predicting nephroprotective effects.
Tan H; Wang F; Hu J; Duan X; Bai W; Wang X; Wang B; Su Y; Hu J
J Appl Toxicol; 2023 Oct; 43(10):1421-1435. PubMed ID: 37057715
[TBL] [Abstract][Full Text] [Related]
36. Prediction of clinical drug-drug interactions of veliparib (ABT-888) with human renal transporters (OAT1, OAT3, OCT2, MATE1, and MATE2K).
Kikuchi R; Lao Y; Bow DA; Chiou WJ; Andracki ME; Carr RA; Voorman RL; De Morais SM
J Pharm Sci; 2013 Dec; 102(12):4426-32. PubMed ID: 24122511
[TBL] [Abstract][Full Text] [Related]
37. Editor's Highlight: PlacentalDisposition and Effects of Crizotinib: An Ex Vivo Study in the Isolated Dual-Side Perfused Human Cotyledon.
Eliesen GAM; van den Broek P; van den Heuvel JJ; Bilos A; Pertijs J; van Drongelen J; Russel FGM; Greupink R
Toxicol Sci; 2017 Jun; 157(2):500-509. PubMed ID: 28369651
[TBL] [Abstract][Full Text] [Related]
38. Impact on creatinine renal clearance by the interplay of multiple renal transporters: a case study with INCB039110.
Zhang Y; Warren MS; Zhang X; Diamond S; Williams B; Punwani N; Huang J; Huang Y; Yeleswaram S
Drug Metab Dispos; 2015 Apr; 43(4):485-9. PubMed ID: 25605813
[TBL] [Abstract][Full Text] [Related]
39. Incorporating renal excretion via the OCT2 transporter in physiologically based kinetic modelling to predict in vivo kinetics of mepiquat in rat.
Noorlander A; Wesseling S; Rietjens IMCM; van Ravenzwaay B
Toxicol Lett; 2021 Jun; 343():34-43. PubMed ID: 33639197
[TBL] [Abstract][Full Text] [Related]
40. Wedelolactone protects against cisplatin-induced nephrotoxicity in mice via inhibition of organic cation transporter 2.
Wang G; Bi Y; Xiong H; Bo T; Han L; Zhou L; Zhang C; Zhang Y
Hum Exp Toxicol; 2021 Dec; 40(12_suppl):S447-S459. PubMed ID: 34592875
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
